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Acute effects of physiological increments of a.atrial natriuretic peptide
in man. Seven dehydrated volunteers received three hour infusions of
0.8 pmol kg min of human a-atrial natriuretic peptide (h-aANP) or
vehicle alone (Ve) in a single-blind, randomized cross-over design.
H-aANP infusion increased plasma h-aANP from 4.2 0.4 to 20.3
6.4 pt. H-aANP suppressed plasma renin activity from 3.30 0.48 to
1.37 0.35 ng ml hr (P < 0.001 vs. Ve). Plasma aldosterone was
unaltered by h-aANP. Fractional excretion of filtered sodium (FENa)
changed from 0.92 0.09 to 1.13 0.16% with h-aANP, and from 1.02
0.09 to 0.69 0.11% with Ve (P < 0.01 h-aANP vs. Ve). FEK was
unchanged. FE4 increased from 7.2 1.2 to 9.2 1.2% and FELl
from 22.1 1.4 to 24.9 3.0% with h-aANP (both P < 0.05 vs. Ve).
H-aANP decreased mean urinary osmolality by approximately ISO
mOsmol kg compared to Ve (P < 0.01). GFR, RPF and filtration
fraction were unchanged by h-aANP. H-aANP was associated with a
significant tachycardia (P < 0.01 vs. Ve) but with no significant change
in arterial pressure. These results suggest that small increments of
plasma h-aANP, mimicking physiological changes, are natriuretic at
least partly by reducing proximal tubular reabsorption of sodium, and
also impair urinary concentration.
[10], also suggest that these peptides depress the fractional
reabsorption of sodium by the proximal tubule. Studies in dogs
have provided evidence that a similar proximal effect occurs
even with small infusions of ANP, giving physiological circu-
lating levels [1]. Consequently, endogenous ANP might poten-
tiate the other proximal tubular natriuretic effects of saline
infusions in the dog. The natriuretic mechanisms of very small
infusions of h-aANP have not been investigated in man. There-
fore, the present study used clearance techniques to assess the
main renal sites of action of physiological increments of exog-
enous h-aANP in normal volunteers. In particular, lithium
clearance was used as a measure of fluid delivery from the
proximal tubule to the loop of Henle and beyond [11—131.
Methods
Studies were conducted with the approval of the local Ethical
Committee and with the informed consent of each volunteer.
Atrial natriuretic peptide (ANP), released by stretch of the
cardiac atria, may be one of the many factors that influence
renal sodium excretion when the extracellular fluid volume is
expanded [I]. Recently, however, it has been suggested that the
natriuretic potency of ANP may be too small to account for a
significant proportion of the acute natriuresis of volume expan-
sion in man [21. The single detailed report of the acute natri-
uretic action of physiological increments of exogenous human
a-ANP (h-aANP) in man appears to be consistent with this
suggestion [3]. Moreover, another group has reported that
approximately equimolar, small infusions of a close synthetic
analogue of h-aANP are also poorly natriuretic [4, 5]. Never-
theless, endogenously released h-aANP might still be necessary
to potentiate other natriuretic mechanisms entrained by volume
expansion. Intravenous infusions of saline can reduce proximal
tubular sodium reabsorption in a number of ways, and this
reduction in tubular reabsorption is important to their natri-
uretic effect [6—8]. Clearance studies in man using relatively
large infusions of h-aANP [9], or of close synthetic analogues
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Seven normal male volunteers (aged 25 to 36 years) were
studied on two days, each at least one week apart. On the day
before each study, subjects ingested 500 mg of lithium carbon-
ate with 20 ml of water at 2300 hours. Otherwise, they neither
ate nor drank from 2100 hours on the day before each study
until the end of each study.
At 0830 hours on each day, 5 ml of venous blood was drawn
for measurements of inulin and para-aminohippurate plasma
blanks, and then subjects received an intravenous loading dose
of 10% wt/vol inulin (50 mg kg; Laevosan Geselltschaft,
Austria) and 20% wt/vol sodium para-aminohippurate (8 mg
kg; Merck, Sharp & Dohme, West Point, Pennsylvania,
USA). Inulin was then infused intravenously at 33 mg min'
and sodium para-aminohippurate at 12 mg min' throughout
each study.
On each day, subjects voided their bladders at 0930 hours and
remained quietly seated except to pass hourly collections of
urine until 1330 hours. After the baseline collection between
0930 and 1030 hours, they received an intravenous infusion of
0.8 pmol kg min of synthetic h-aANP(BissendorfPeptides,
FRG) until 1330 hours on one day, and its vehicle alone on the
other, in single blind random order. The h-aANP was dissolved
in a vehicle of4l ml of 0.9% sodium chloride plus 4 ml of human
serum albumin (Evans Medical, Merseyside, UK) and infused
at IS ml hr'. The peptide was assayed by high performance
liquid chromatography as described previously [9]. It contained
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only one chromatographic peak, corresponding to the running
position of h-aANP.
On each day, 5 ml blood samples were drawn at 0928, 1028,
1128, 1228 and 1328 hours for measurements of plasma electro-
lytes, phosphate, osmolality, inulin and para-aminohippurate.
Additional 15 ml blood samples were drawn at 1028, 1128, 1228
and 1328 hours for measurements of total plasma protein,
plasma renin activity (PRA), aldosterone and h-aANP. Five ml
aliquots for assay of h-aANP were drawn into pre-chilled
polypropylene tubes (Sarstedt, UK) containing sufficient dipo-
tassium EDTA and aprotonin (Bayer, UK) to give respective
final concentrations of 1 mg ml' and 1000 kallikrein inhibitory
units per ml. All blood was centrifuged immediately at 4°C.
Plasma was snap frozen and stored under liquid nitrogen.
Arterial pressure was recorded automatically (Dinamap, Cri-
tikon Inc., USA) in triplicate every hour from 1025 hours on
each day. Mean arterial pressure (MAP) was calculated as the
diastolic pressure plus one third of the difference between the
systolic and diastolic pressures [14].
Plasma and urine were assayed for electrolytes by flame
photometry, for osmolality by depression of dew point, for
inulin by an acid resorcinol method [15], for para-aminohippu-
rate by a diazo-dye method [16], and for urea, phosphate and
total protein by a routine autoanalyzer (SMAC, Technicon,
Tarrytown, New York, USA). PRA and plasma aldosterone
concentrations were measured by radioimmunoassay kits (CIS,
Ltd, UK). Plasma h-aANP was measured by radioimmunoas-
say after extraction using C8 Bond Elut columns (Jones Chro-
matography, UK), as described in detail elsewhere [17].
Results are presented as means their standard errors.
Comparison of trends over time was by three-way analysis of
variance, selecting the variation with time, with h-aANP versus
placebo and from subject to subject as the three factors tested
(BMDP Statistical Software Inc., USA). Means were compared
by paired (-tests. Linear regressions were calculated by the
method of least squares. Standard deviations of regression
coefficients were found by analysis of variance, and compari-
sons of regression lines were made by two-way analysis of
variance using the t distribution [181.
The clearances of plasma solutes were calculated in the usual
way. GFR was measured by C1 and effective RPF by CPAH.
CLI is a measure of fluid delivery from the proximal tubule to
the loop of Henle [9—11), so that FeL, (=C1 IGFR) is a measure
of the fraction of filtered fluid delivered from the proximal
tubule. CN/CLl is then a measure of that fraction of the sodium
delivered to the distal tubule which is finally excreted. Simi-
larly, the ratio of the rate of urinary flow to C1, (V/CLI) is a
measure of that fraction of the water delivered to the distal
tubule which is finally excreted [II]. Solute-free water reab-
sorption (T,0) was calculated as
TH,o =
(Uosm
—
1)
x v
'O
where Uosm and POsm are respectively the simultaneous urinary
and plasma osmolalities [19].
Results
Plasma hormones and plasma protein
The infusion of 0.8 pmol kg min of h-aANP increased
plasma immunoreactive h-aANP to approximately 20 M for
the last two hours of infusion. Plasma immunoreactive h-aANP
did not change significantly during the time-control day (Fig.
IA).
The infusion of h-ANP sharply suppressed PRA. Thus, PRA
had decreased compared to its time control even by the end of
the first hour of h-aANP infusion (P < 0.01; Fig. IB). In
contrast, there were no significant differences between the
concentrations of plasma aldosterone on the days with h-aANP
infusion compared to those with vehicle alone (Fig. IC).
There were no significant changes in plasma protein concen-
tration, either during infusion of h-aANP or of vehicle alone, or
comparing the two treatments. Plasma protein concentrations
were respectively 72 2 and 72 2 gl' in the basal and last
hour of the control day, and 70 I and 71 gl at the
corresponding times on the day with h-aANP.
Arterial pressure and heart rate
During infusion of h-aANP, MAP fell by 2 to 3 mm Hg
compared with its level before infusion, but this trend did not
differ significantly from that with placebo (Fig. 2A). However,
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Fig. 1. Changes in plasma h-aANP concentration (A), PRA (B) and
plasma aldosterone concentration (C) during infusion of 0.8 pmol kg'
min' of h-aANP (solid lines) or its vehicle (dashed lines) in seven
normal volunteers. Infusions given during hatched bars. '"' = P <
0.001 comparing trends over time with h-aANP and with vehicle alone.
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h-aANP infusion produced a significant tachycardia compared
to the control day (Fig. 2B). Moreover, two subjects com-
plained of light-headedness during the last hour of the infusion
of h-aANP.
Water and solute excretion
The infusion of h-aANP increased V significantly above that
on the control day (Fig. 3A). H-aANP also significantly de-
creased urinary osmolality by about 150 mOsmol kg' com-
pared to the control day (Fig. 3B). Indeed, Uosm fell to 214 m
Osmol kg' during peptide infusion in one subject, at a time
when Osm was 288 mOsmol kg. Consistent with these
changes, the fractional excretion of water delivered to the distal
tubule was significantly increased by h-aANP (Fig. 3C). How-
ever, the infusion of h-aANP did not significantly alter the trend
of mean TH,o compared to the control day (Table 1).
There were no significant differences in the initial values of
UNaV, UKV, FENa, FEK, CL, FEL3, U,04V or FE0 between
the control day and the day with h-aANP. On the control day,
there was a steady fall in UNaV (Table I) and FENa (Fig. 4A).
In contrast, both mean UNaV and mean FENa rose by approx-
imately 25% of their initial values by the end of the infusions of
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Fig. 3. Changes in urinaly flow (A), osmolality (B) and fractional
excretion of the distal load of water measured as V/CLI (C) during
infusion of 0.8 pmol kg" min' of h-aANP (solid lines) or if s vehicle
(dashed lines) in seven normal volunteers. Infusions given during
hatched bars. * = P<0.05, < 0.01 comparing trends over time with
h-aANP and with vehicle alone.
h-aANP (Table 1, Fig. 4A). There were no significant differ-
ences in potassium excretion between the days with h-aANP
and the control days (Table I, Fig. 4B).
The infusions of h-aANP significantly increased both CL
(Table I) and FELl (Fig. 4C) compared to the control day. The
peptide infusions also significantly increased FEB04 compared
to the control day (Table 1). These changes are consistent with
a reduction of the tubular reabsorption of lithium and phos-
phate, and together suggest that the infusions of h-aANP
depressed the reabsorption of fluid from the proximal tubule.
The infusions of h-aANP also significantly increased the ratio
CNa/CLi, a measure of the fractional excretion of luminal
sodium reaching the distal tubule (Table 1). However, Figure 5
suggests that changes in this ratio were probably related to the
prevailing rate of sodium excretion, occurring either diurnally
or with h-aANP infusion. Thus, the coefficient for the regres-
sion of CNa/CLI on CNa was 2.42 0.93% per ml min for the
basal hour of the control day, 3.14 1.85% per ml min' for the
basal hour of the day with peptide infusion, 3.17 1.61% per ml
min for the final hour of the control day and 3.77 1.85% per
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Fig. 2. MAP (A) and heart rate (B) during infusion of 0.8 pmol kg-i
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Table 1. Changes in urinary parameters on control day and with h-csANP infusion
Control day ANP day
Hours I 2 3 4 I 2 3 4
GRE ml min 129 8 128 7 133 9 126 9 128 6 127 7 125 7 129 8
RPF ml min' 717 38 669 55 706 32 704 45 713 47 736 37 687 57 716 56
Filtration fraction % 18.3 1.4 19.6 1.1 18.9 1.0 17.9 0.9 18.2 1.0 17.5 1.2 18.7 1.5 18.4 1.3
UNaV .unolmin' 184 17 183 21 152 19 119 19 160 11 181 22 188 23 202 22b
tJKVianoImin'
U4V i.unolmin'
Uora M
74±12
6.8 1.0
312 12
85±9
6.5 0.7
303 19
88±11
6.3 0.5
339 24
76±9
6.9 0.7
370 29
81±13
7.1 1.1
317 25
91±10
7.4 0.6
277 32
87±8
8.1 0.9
243 39
76±7
9.3 I.l
252 32C
FE4 %
TH2O ml min'
CNUmlmin'
CLI ml min'
CNa/CL1 %
6.9 1.2
1.77 0.14
1,32 0.13
26.9 1.5
4.91 0.40
6.5 0.9
1.70 0.18
1.31 0.15
27.8 1.4
4.77 0.52
6.2 0.7
1.66 0.10
1.09 0.13
25.8 1.4
4.29 0,51
6.7 0.9
1.48 0.13
0.85 0.14
24.0 1.9
3.58 0.49
7.2 1.2
1.71 0.08
1.15 0.08
28.2 2.1
4.20 0.41
7.5 0.8
1.73 0.18
1.30 0.15
29.5 2.2
4.44 0.50
8.0 1.0
1.33 0.37
1.34 0.16
29.0 2.0
4.72 0.63
9.2 1.2k
1.63 0.23
1.44 0.l6'
31.0 2.4a
4.85 0.65"
a p < 0.05, b p < 0.01, ' P < 0.001 for comparison of the trend over time on the ANP day with that on the control day
mm min' for the final hour during peptide infusion. There were
no significant differences between these coefficients and neither
were there any significant differences in the positions of their
corresponding regression lines.
Finally, neither GFR nor RPF nor filtration fraction changed
significantly on either the control day or the day with infusion of
h-crANP (Table I). Similarly, these parameters did not differ
significantly between the two days.
Discussion
This study documents a clear natriuretic effect of the smallest
rate of sustained infusion of h-aANP to be administered so far
in man. However, it questions whether the release of endoge-
nous h-aANP is a major independent cause of the natriuresis of
acute plasma volume expansion. The infusions of 0.8 pmol kg'
min'" of h-aANP (Fig. IA) mimicked the maximum plasma
concentrations of endogenous h-aANP, of about 20 p, which
occur with intravenous infusion of 2 liters of isotonic saline over
one hour [20, 21] or with head-out water immersion [22].
Despite this, both saline infusion and head-out immersion
increase sodium excretion by 100 to 200% above its baseline
[20—22), whereas h-aANP increased sodium excretion by only
about 25% (Table I, Fig. 4A). This discrepancy is accentuated
by the fact that the maximum level of plasma h-aANP is poorly
sustained beyond one hour from the start of saline infusion or
head-out immersion [20—22), but is well sustained with infusions
of h-crANP (Fig. IA). Moreover, sodium excretion increases to
its maximum by two hours after the start of saline infusion [20,
21] or of head-out immersion [22], whereas it increases more
gradually with the infusions of h-aANP (Table 1, Fig. 4A). A
number of others have also infused h-aANP at rates of 1.2 to 30
pmol' min' in normal volunteers, but it is only with the
highest rates of infusion, which achieve pathological levels of
plasma h-aANP, that rates of sodium excretion match or
exceed those caused by infusions of 2 liters of isotonic saline [3,
9, 23—25]. Similarly, infusions of close synthetic analogues
which are equimolar to the lower rates of infusion of h-aANP
are poorly natriuretic [4, 5]. A diet low in sodium can attenuate
the natriuretic response to h-aANP [26]. The dietary sodium
content was not specified for our volunteers. However, several
previous studies have shown that the rate of sodium excretion
in dehydrated volunteers depends partly on a diurnal cycle and
partly on the dietary intake of sodium [13, 27—29]. Thus, the
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FIg. 4. Changes in FEN, (A), FEK (B), and FE,, (C) during infusion of
0.8 pmol kg-I mm -' of h-o.ANP (solid lines) or its vehicle (dashed lines)
in seven normal volunteers. Infusions given during hatchedbars. * =
<0.05, ** = P < 0.01 comparing trends over time with h-aANP and
with vehicle alone.
baseline morning sodium excretion in our volunteers corre-
sponds to that seen under almost identical conditions in a
previous study from this laboratory in which the same dehy-
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drated subjects were studied while taking diets providing more
than 200 mmol of Na per day [13]. Therefore, the most
straightforward implication of the present results is that h-
aANP, acting by itself, is not an adequate explanation of the
acute natriuretic effects of saline infusion or head-out water
immersion in man.
However, this conclusion needs some reservations since the
absolute measurements of plasma levels of h-aANP may not be
directly comparable between different laboratories because of
differences in the characteristics of each radioimmunoassay [2].
Comparisons of relative changes may be less influenced by
some of these differences. Thus, the infusion of 0.8 pmol kg
min of h-aANP used here increased the plasma concentration
of h-aANP from 4.2 0.4 to 19.2 6.4 p, an almost fivefold
change. However, intravenous infusions of 2 liters of isotonic
saline and head-out water immersion both produce, if anything,
smaller increases of up to threefold above baseline [20—22).
Similarly, using the present assay, infusions of 2 liters of
isotonic saline given over one hour increased the plasma
concentration of h-aANP from 5.3 0.4 to 15.1 4.6 M in six
healthy volunteers (Brown, unpublished observations). In gen-
eral, therefore, the results imply that endogenously released
h-aANP may be, by itself, a relatively weak natriuretic agent.
Nevertheless, it should be said that the natriuretic effects of
placebo, of small infusions of h-aANP and of plasma volume
expansion have not been compared in the same cohort of
experimental subjects. Further caution is necessary because the
temporal pattern of the release of endogenous h-aANP has not
been studied closely and may modify responses compared to
continuous infusion of the exogenous peptide such as used
here.
Another confounding factor could be that endogenous h-
aANP may act by potentiating other natriuretic agents also
entrained by saline infusion or head-out immersion. For exam-
ple, an important natriuretic effect of saline infusions is to
depress the fractional reabsorption of filtered sodium by the
proximal tubule [6]. Several mechanisms can contribute to this
[6—8], and pharmacological doses of ANP are already known to
interact with such mechanisms [30—32]. A proximal tubular
natriuretic action is also suggested by the effects of the present
small infusions of h-aANP on phosphate and lithium excretion.
Phosphate excretion is a qualitative marker of proximal sodium
reabsorption but, as such, is complicated by the possibility of
significant distal tubular phosphate reabsorption [33]. The distal
tubule also reabsorbs lithium, but this seems to be significant
only in sodium-deprived animals [II, 34], and there is evidence
that it is not significant in man 1FENa exceeds 0.2% [12]. Thus,
in subjects such as those of the present study, FEL, seems to be
a useful marker for the fractional reabsorption of sodium by the
proximal tubule [Il, 12]. Large infusions of h-aANP, giving
pathologically high levels of circulating peptide, increase GFR
[9, 25] so that changes in FEB04 and FEL, could be non-specific
tubular adjustments to this. However, ANP has recently been
reported to depress proximal tubular reabsorption more than
glucagon, despite similar increases in GFR with both agents
[36]. Thus, large infusions of h-aANP probably reduce frac-
tional sodium reabsorption from the proximal tubule indepen-
dently of increases in GFR [9, 36]. The much smaller infusions
of h-aANP given here did not increase C1 significantly, but
increased FELl (Fig. 4C) and FEB04 (Table I). Urinary flows
were relatively small in our dehydrated volunteers so that dead
space errors might have obscured small changes in GFR.
Systematic changes in other clearances, in CNa and CL,, were,
nevertheless, large enough to be detected. Large infusions of
h-aANP, which increase C1,,, also increase filtration fraction
substantially [26]. Dead space errors in the individual clearance
measurements will cancel in this ratio. Therefore, the lack of an
increase in filtration fraction with the present infusions of
h-aANP argues again that their glomerular effects were atten-
uated compared to their effects on the proximal tubule. This
would be consistent with results in dogs, in which small
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infusions of ANP increase CLI, FELl and FEB04, but not GFR
[1].
The infusions of h-aANP given here increased the ratio
CNa/CLI. This could mean that h-aANP specifically depresses
the fractional reabsorption of sodium from the distal tubule [10].
However, Figure 5 raises the possibility that the changes in
CNa/CLj may have been non-specific since similar changes
occurred diurnally. Although some of the four individual regres-
sions shown in Figure 5 do not themselves achieve statistical
significance, similar and significant relationships between CNa/
CLI and sodium excretion, with regression coefficients indistin-
guishable from those found here, have already been described
with other proximally acting diuretics such as captopril [13] and
acetazolamide (Brown, manuscript in preparation). Such di-
uretics probably alter CN/CL in proportion to their natriuretic
effects by causing non-specific adjustments of distal fractional
reabsorption in response to changes in the luminal delivery of
sodium from more proximal nephron segments [131.
Despite a fall in PRA, infusion of h-aANP did not signifi-
cantly alter plasma aldosterone concentration compared to
infusion of vehicle alone (Fig. lC). Studies in the rat suggest
that the threshold concentration of plasma a-ANP for renin
suppression is lower than that for aldosterone suppression [371.
Higher plasma levels of exogenous rat a-ANP suppressed
aldosterone levels without causing further reductions in PRA
[37]. Thus, a-ANP seems to control renin and aldosterone
levels by independent mechanisms in the rat. Similarly, our
results suggest that low concentrations of h-aANP selectively
suppress PRA in man as well. Moreover, the infusions of
h-aANP did not reduce potassium excretion significantly (Table
1, Fig. 4B), and this also argues against a role for aldosterone
suppression in the acute natriuretic effect of h-aANP [38].
However, the infusions of h-aANP did suppress PRA sharply
and quickly (Fig. IB), confirming previous findings in man [3].
Antagonists of the renin-angiotensin system in man exert a
major acute natriuretic action on the proximal tubule [13]. For
example, captopril can produce larger increases in UNaV and
FELl than those caused by h-aANP infusions in the present
study [13]. Consequently, the early suppression of PRA with
small increments of h-aANP may be responsible for an impor-
tant part of the subsequent decrease in proximal tubular fluid
reabsorption. Cyclic GMP is thought to be an intracellular
second messenger for atrial peptides; but atrial peptides given
alone do not stimulate cyclic GMP production in proximal
tubular cells [39], and given alone, they do not alter fluid
reabsorption by the isolated perfused proximal tubule [40].
Early micropuncture work found no evidence for a specific
reduction in the fractional reabsorption of sodium by the
proximal tubule of superficial nephrons during infusions of
atrial peptides [41]. However, more recently such a reduction
has been found to occur upstream of the bend of the loop of
Henle in juxtamedullary nephrons of young rats [42], and, most
recently, it has been reported that atrial peptides increase the
fractional delivery of filtered sodium to the collecting duct [43].
These disparate findings would be explained if atrial peptides
depress proximal tubular sodium reabsorption indirectly, by
inhibiting angiotensin II production. Moreover, atrial peptides
can locally inhibit the stimulatory effect of angiotensin 11 on
proximal tubular fluid reabsorption in the rat [44]. Indeed, in
man, pretreatment with captopril prevents the increased excre-
tion of sodium [45, 46] and lithium [46, 47] caused by infusions
of h-aANP, further suggesting that endogenous angiotensin H
may be necessary to the natriuretic actions of h-aANP.
The infusions of h-ANP given here caused Usm to fall to
approximately 150 mOsmol kg below that on the control day.
This suggests that physiological increments of h-aANP them-
selves impair the countercurrent mechanism of urinary concen-
tration, and it was consistent with this that the fractional
excretion of water delivered beyond the proximal tubule (V/
CLI) increased significantly (Fig. 3C). Urinary concentration
can fall because of the dilution of passively transported solutes
by increasing urinary flow [48]. Thus, for example, Uurea fell
sharply with h-aANP (Table 1). Although some urinary dilution
because of a fall in Uurea probably occurs with all proximally
acting diuretics, at least two, captopnl and acetazolamide, still
increase THo in proportion to sodium excretion in man [13, 19].
This is consistent with the increased rate of medullary solute
reabsorption that occurs as more luminal sodium is presented to
the loop of Henle [191. In the present study, h-xANP increased
sodium excretion but not TH,o compared to the control day
(Table I). This suggests that h-aANP impaired the mechanism
of urinary concentration over and above its effects on
One possibility is suggested by evidence in man that h-aANP
can antagonise the V2 receptor-mediated effects of antidiuretic
hormone on the distal tubular epithelium [491. In one subject of
the present study, the infusion of h-aANP produced a urine
which was hypotonic to plasma; such urine can only be pro-
duced if the hydraulic conductivity of the distal tubular epithe-
hum is sufficiently low to preserve the hypotonicity of the
tubular fluid established in the thick ascending limb of the ioop
of Henle [49]. This could be caused by a reduction in the
circulating concentrating of antidiuretic hormone or by antago-
nism of its effects on epithelial hydraulic conductivity [491.
Intravenous infusions of saline represent water loads as well as
sodium loads. They not only increase UNaV, but can also
increase water excretion and can even cause a hypotonic urine
[50]. Release of endogenous h-aANP could be an important
direct or facilitatory cause of this latter component of the
regulation of the extracellular fluid volume.
Finally, the present infusions of h-aANP were associated
with tachycardia. The effects of a mild arterial vasodilator, such
as h-aANP [2], may have been especially pronounced in our
dehydrated, non-recumbent subjects, and two subjects did feel
syncopal during peptide infusion. A baroreceptor-mediated
tachycardia occurs with a wide variety of arterial vasodilators
in man, the effects of small doses of the vasodilators on MAP
being compensated by increases in sympathetic nerve activity
[51, 52]. However, although MAP fell during infusion of h-
aANP, the fall was not statistically significant and the steady
state fall in MAP was only 2 mm Hg. Hypovolemia caused by
h-aANP could also stimulate sympathetic nervous activity by
reflex, but it is unlikely to have made a substantial contribution
in the present study because urinary sodium losses on the day
with h-aANP exceeded those on the control day by less than 7
mmol. Larger infusions of h-aANP also translocate extracellu-
lar fluid out of the plasma compartment [2], but the plasma
protein concentration did not rise significantly with the small
infusions given here. Therefore, further studies are necessary to
elucidate the mechanism of tachycardia in our protocol.
In conclusion, this study demonstrates that small increments
Brown and O'Flynn: Effects of physiological increments of h-a.4NP 651
in circulating h-aANP, similar to those arising endogenously in
healthy individuals, are distinctly natriuretic and are powerful
suppressors of PRA. The acute natriuresis probably occurs at
least partly because proximal tubular sodium reabsorption is
reduced. If the natriuretic potency of these increments of
h-aANP is sustained long-term, it could make important con-
tributions to sodium balance, especially in conditions, such as
mineralocorticoid escape [53], in which prolonged elevations of
the circulating concentration of h-aANP occur. The effects of
small increments of h-aANP on water excretion also merit
further investigation as part of the acute and long term re-
sponses of the body to changes in extracellular fluid or plasma
volume.
Reprint requests to Dr. J. Brown, The Physiological Laboratory,
University of Cambridge, Downing Street, Cambridge CB2 3EG, En-
gland, United Kingdom.
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